Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.
BACKGROUND
It is well known that iron overload may cause multiple organ failure. In chronically transfused patients, optimal iron chelation therapy is associated with reduced morbidity and mortality. Furthermore, chelation therapy has been associated with erythroid responses.


METHODS
Among chronically transfused adults affected by myeloproliferative neoplasms and treated with iron chelators, two case reports are described.


METHODS
A male adult patient with myelodysplastic syndrome (MDS) and a female adult with aplastic anemia (AA), both transfusion-dependent, were treated with deferasirox, an oral iron chelator.


RESULTS
A significant reduction in transfusion requirement was observed and was dependent on chelation therapy. The patient affected by AA also experienced a significant increase in hemoglobin levels. Minimal doses of deferasirox maintained the erythroid responses. Many mechanisms of action of the drug on erythropoiesis have been postulated. The early erythroid response seems to be independent of the removal of iron from deposits, per se, since the reduction of ferritin levels (a surrogate marker of iron deposits) below threshold levels occurs as a later event.


CONCLUSIONS
Although there are few reports on erythroid responses in patients undergoing iron chelation therapy, they may give new insights in the pathogenesis of MDS and other myeloproliferative neoplasms. AA may benefit in terms of erythroid response. The findings in these cases underline the clinical importance of treating patients with iron overload. A survival benefit of chelation in patients with myeloproliferative neoplasms is still to be confirmed.
Hematology Division, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy. estheroliva@hotmail.com
Esther Natalie
EN
Oliva
Francesca
F
Ronco
Antonio
A
Marino
Caterina
C
Alati
Giulia
G
Praticò
Francesco
F
Nobile
D000741:Anemia, Aplastic / Q000097:blood / Q000628:therapy; D001565:Benzoates / Q000627:therapeutic use*; D001803:Blood Transfusion; D000077588:Deferasirox; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000628:therapy; D014230:Triazoles / Q000627:therapeutic use*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox